Hormonal therapy: historical perspective to future directions
- PMID:12667881
- DOI: 10.1016/s0090-4295(02)02393-2
Hormonal therapy: historical perspective to future directions
Abstract
Prostate cancer is second only to lung and bronchial cancer as the leading cause of cancer death in men. Local treatment, surgery, and radiation remain the mainstay of treatment for early-stage disease. However, in locally advanced and advanced disease, there has been considerable evolution in the hormonal therapies. Suppression of testosterone production, the primary goal of hormonal therapy, may be accomplished with the use of estrogens, antiandrogens, and agonists and antagonists of luteinizing hormone-releasing hormone (LHRH). This article provides an overview of the primary hormonal therapies currently used in prostate cancer. Estrogen therapy was initially the predominant medical form of hormone manipulation and an alternative to orchiectomy. However, serious thrombogenic side effects were associated with its use, which decreased after the introduction of LHRH agonists in the 1980s. Many of the side effects occurring with oral estrogen therapy may be modulated by parenteral administration, and thus estrogen use is being revisited. LHRH agonists effectively reduce testosterone levels to castration levels (<50 ng/mL) within 2 to 4 weeks, although their use is associated with tumor flare. Antiandrogen monotherapy may offer quality-of-life benefits over treatment with androgen deprivation. The additive benefit of combined androgen blockade is yet to be determined. Recent evidence suggests that hormonal therapy may offer a survival benefit when initiated in earlier stages of prostate cancer. Future investigations will be directed to determining the most efficacious regimens.
Similar articles
- Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K.Seidenfeld J, et al.Evid Rep Technol Assess (Summ). 1999 May;(4):i-x, 1-246, I1-36, passim.Evid Rep Technol Assess (Summ). 1999.PMID:11098244Free PMC article.Review.
- Hormone therapy of prostatic bone metastases.Huben RP.Huben RP.Adv Exp Med Biol. 1992;324:305-16. doi: 10.1007/978-1-4615-3398-6_33.Adv Exp Med Biol. 1992.PMID:1492625Clinical Trial.
- Hormonal therapy of prostate cancer.Debruyne F.Debruyne F.Semin Urol Oncol. 2002 Aug;20(3 Suppl 1):4-9. doi: 10.1053/suro.2002.35051.Semin Urol Oncol. 2002.PMID:12198632Review.
- Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.Bayoumi AM, Brown AD, Garber AM.Bayoumi AM, et al.J Natl Cancer Inst. 2000 Nov 1;92(21):1731-9. doi: 10.1093/jnci/92.21.1731.J Natl Cancer Inst. 2000.PMID:11058616
- Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ.Seidenfeld J, et al.Ann Intern Med. 2000 Apr 4;132(7):566-77. doi: 10.7326/0003-4819-132-7-200004040-00009.Ann Intern Med. 2000.PMID:10744594
Cited by
- An update on androgen deprivation therapy for prostate cancer.Sharifi N, Gulley JL, Dahut WL.Sharifi N, et al.Endocr Relat Cancer. 2010 Oct 29;17(4):R305-15. doi: 10.1677/ERC-10-0187. Print 2010 Dec.Endocr Relat Cancer. 2010.PMID:20861285Free PMC article.Review.
- DNA methylation of the RIZ1 gene is associated with nuclear accumulation of p53 in prostate cancer.Hasegawa Y, Matsubara A, Teishima J, Seki M, Mita K, Usui T, Oue N, Yasui W.Hasegawa Y, et al.Cancer Sci. 2007 Jan;98(1):32-6. doi: 10.1111/j.1349-7006.2006.00338.x.Cancer Sci. 2007.PMID:17052263Free PMC article.
- Androgen receptor splice variants and prostate cancer: From bench to bedside.Wadosky KM, Koochekpour S.Wadosky KM, et al.Oncotarget. 2017 Mar 14;8(11):18550-18576. doi: 10.18632/oncotarget.14537.Oncotarget. 2017.PMID:28077788Free PMC article.Review.
- Risk stratification in the hormonal treatment of patients with prostate cancer.Uhlman MA, Moul JW, Tang P, Stackhouse DA, Sun L.Uhlman MA, et al.Ther Adv Med Oncol. 2009 Sep;1(2):79-94. doi: 10.1177/1758834009340164.Ther Adv Med Oncol. 2009.PMID:21789114Free PMC article.
- Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer.Lee TY, Pierrillas PB, Lin YW, de Greef R, Zandvliet AS, Schindler E, Migoya E.Lee TY, et al.Clin Pharmacol Ther. 2023 Jan;113(1):124-134. doi: 10.1002/cpt.2743. Epub 2022 Oct 18.Clin Pharmacol Ther. 2023.PMID:36073238Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical